The United Kingdom and the United States have finalized a important trade agreement that will keep zero tariffs on UK medicine shipments entering the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has agreed to increase expenditure on pharmaceuticals through the public health system. This pledge secures that duties on these key goods will be held at zero for a duration of 36 months.
This development follows recent statements to significantly raise tariffs on branded drug products, with increases mentioned as high as 100%.
"This agreement between the Britain bolsters the international landscape for cutting-edge drugs and introduces long-overdue fairness to transatlantic pharmaceutical trade," an announcement noted.
Trade Impact
Drugs are one of the UK's largest exports to the United States, which is by far the primary buyer for major UK drugmakers.
Statistics reveal that in the one-year period to the end of last September, the UK sold medicines valued at £11.1bn to the US. This value accounted for a significant portion of British export trade in that timeframe.
"This guarantee protects work, boosts capital expenditure and sets the stage for the UK to become a international leader for life sciences," a government official stated.
Detailed NHS Changes
The deal involves several key changes from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to increase total public funding on drugs from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The sum manufacturers must return to the NHS to stay within budget will be limited at fifteen percent. Previously, repayments were more than twenty percent.
Industry Background
This agreement follows a long-running dispute between the drug companies and the British authorities over medicine costs and approval rates.
These tensions were intensified by claims that US customers were paying several times more for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been paused or cancelled, while major investments have been directed toward US facilities.
A senior figure stated that the NHS must increase expenditure on medicines, noting that its spending on drugs had shrunk as a share of its overall budget over the previous ten-year period.
